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https://Endovascular port-a-cath rescue in acute thrombotic superior
vena cava syndromeHanno Amberger, MD,a Iris Baumgartner, MD,a Nils Kucher, MD,b and Marc Schindewolf, MD,a
Bern, Zurich, SwitzerlandABSTRACT
Acute superior vena cava (SVC) syndrome is managed by endovascular recanalization, venoplasty with stenting, and
anticoagulation. It is often associated with central venous catheters. We present a case of a 55-year-old woman with
acute SVC syndrome due to port-a-cath-associated thrombosis of the SVC and the brachiocephalic and subclavian veins
who was treated with catheter-based thrombectomy and local spray thrombolysis, venoplasty, and stent placement.
Port-a-cath restoration was achieved in the same session by endovascular snaring and repositioning. This case demon-
strates that reoperation with surgical catheter removal and reinsertion of central venous catheters with possible
complications (eg, rethrombosis, bleeding) can be avoided by single-session endovascular management. (J Vasc Surg
Cases and Innovative Techniques 2019;5:169-73.)
Keywords: Catheter-directed thrombolysis; Port-a-cath snaring; Port-a-cath-associated thrombosis; Superior vena cava
syndrome; Upper extremity venous thrombosisSuperior vena cava (SVC) syndrome is often associated
with central venous catheters, hemodialysis catheters,
or pacemaker electrodes. Endovascular recanalization
procedures are a mainstay therapy to enable quick relief
from symptoms in these vascular emergencies. Veno-
plasty with stenting is often necessary to ensure a good
long-term result. In situ catheters reaching into the SVC
might be jailed by stent placement between the stent
and the vessel wall in the process and hence could be
compromised in their function.
We report a case in which we chose to perform a
temporary snaring procedure of a port-a-cath tube in
the setting of SVC syndrome to avoid catheter removal
and later reinsertion with the associated risks and
to minimize health care-related cost. The patient con-
sented to publication of this report.
CASE REPORT
A 55-year-old woman (155 cm, 55 kg) who had undergone
hemicolectomy because of an obstructing adenocarcinoma of
the ascending colon 6 months ago presented in the emergency
department because of a progressive swelling of her face and
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doi.org/10.1016/j.jvscit.2019.03.005shortness of breath at rest for the last 12 days. Until 20 days
ago, she had been receiving subsequent adjuvant chemo-
therapy with FOLFOX, which was administered through a port-
a-cath. In addition to the presenting symptoms, the physical ex-
amination showed dilated jugular veins in the upright position.
There were no local signs of infection in the area of the
implanted port-a-cath and no edema of the lower extremities.
Her medical history further showed a substituted hypothyroid-
ism after thyroidectomy for struma nodosa. Initial diagnostic
workup contained a computed tomography scan, which
showed thrombosis of the SVC reaching from the caval conﬂu-
ence of the azygos vein to both brachiocephalic veins into the
left subclavian vein (Fig 1). Vascular compression by a tumor or
lymphadenopathy and pulmonary embolism were ruled out.
Echocardiography showed normal systolic and diastolic
function of the heart, no valvulopathies, and normal-sized left
and right ventricles. No intracardiac clots were detected. Labora-
tory analysis showed normal red and white blood cell counts.
The international normalized ratio was 0.91. All electrolytes,
C-reactive protein, thyroid-stimulating hormone, and kidney
function parameters were within normal range.
Therapeutic procedure and assessment. Because of the
newly diagnosed thrombosis, the patient was treated with a
therapeutic dose of unfractionated heparin (Liquemin; Drossa-
pharm, Basel, Switzerland) and transferred to our hospital for
endovascular revascularization.
We performed venography over the right basilic vein and
conﬁrmed the diagnosis of an occlusion of the SVC. We opted
for a catheter-based thrombectomy (AngioJet 8F ZelanteDVT;
Boston Scientiﬁc, Marlborough, Mass) with PowerPulse spray
delivery of 10 mg of alteplase (Actilyse; Boehringer Ingelheim,
Basel, Switzerland) into the thrombus.1,2 Removal of fresh
thrombotic material revealed extended post-thrombotic
changes in the proximal brachiocephalic vein and the SVC.
To completely unmask the extent of post-thrombotic changes,
we placed a valved-tip, multiple-side hole lysis catheter169
Fig 1. Computed tomography scan (A) and phlebography (B) of thrombosis of the superior vena cava (SVC) and
both brachiocephalic veins (arrow).
Fig 2. High-grade chronic, post-thrombotic stenosis of the
superior vena cava (SVC) at the tip position of the port-
a-cath after AngioJet thrombectomy (arrow).
170 Amberger et al Journal of Vascular Surgery Cases and Innovative Techniques
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thrombolysis during 15 hours (2 mg/h for 5 hours, 1 mg/h for
10 hours). Second-look phlebography the next day further
showed a high-grade (75%), chronic, post-thrombotic stenosis
of the SVC, which was associated with the tip position of the
port-a-cath that had been placed through the left subclavian
vein (Fig 2). To ensure unrestrained venous inﬂow and to pre-
vent secondary SVC syndrome, we decided to perform percu-
taneous transluminal angioplasty and stenting of the lesion.
However, to prevent jailing of the port-a-cath tube by stent
placement to keep it functional in case of future chemo-
therapy and to avoid surgical removal and the need for reim-
plantation with subsequent risk of thrombosis progression
during perioperative pausing of anticoagulation, endovascular
repositioning of the port-a-cath tube before percutaneous
transluminal angioplasty and stenting was considered in a ﬁrst
approach. Over an 8F sheath access in the right basilic vein, the
stenosis was passed using a 0.035-inch guidewire (Radiofocus
Guidewire M, stiff type; Terumo, Tokyo, Japan) and a Navicross
support catheter (Terumo). Afterward, a snare (Atrieve Vascular
Snare Kit 18-30 mm; Argon Medical Devices, Plano, Tex)
was inserted over a delivery catheter, and the tip of the
port-a-cath was captured in the SVC and pulled back into
the right brachiocephalic vein (Fig 3). Then, balloon angioplasty
(Atlas Gold 12/40 mm; Bard Peripheral Vascular, Tempe, Ariz),
stent implantation (sinus-XL, 18/60 mm; OptiMed, Ettlingen,
Germany), and postdilation (Atlas Gold 14/40 mm) were per-
formed over a 10F sheath (Avanti sheath introducer; Cordis,
Miami Lakes, Fla) access in the right common femoral vein.
After successful stent implantation, the catheter was snared
from the right common femoral vein and pulled back into
the stent (Fig 4). Venography at the end of the examination
showed an unrestricted venous inﬂow (Fig 5).
An oral anticoagulation regimen with rivaroxaban 15 mg twice
daily was initiated for 3 weeks, followed by 20 mg every day.
The follow-up visit after 3 months showed no clinical signs of a
stent occlusion. Duplex ultrasound conﬁrmed normal venousinﬂow. The port-a-cath was still in situ with regular function. A
decision was made to continue the anticoagulation regimen
with rivaroxaban until port-a-cath explantation.
DISCUSSION
An SVC syndrome caused by a lumen-obstructing
thrombosis is often associated with central venous
Fig 3. A and B, Snaring of the port-a-cath tube from the superior vena cava (SVC) into the right brachiocephalic
vein using an Atrieve Vascular Snare Kit 18-30 mm (Argon Medical Devices, Plano, Tex).
Fig 4. A and B, Snaring of the catheter from the right common femoral vein back into the stent using an Atrieve
Vascular Snare Kit 18-30 mm.
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Volume 5, Number 2catheters or pacemaker electrodes. The growing use of
these central venous devices is reﬂected in increasing
cases of thrombosis of the vena cava,3-5 which occurs in
0.2% to 3.3% of these patients. Prothrombotic conditions
(eg, cancer, chemotherapy, thrombophilia, and external
compression) increase the risk of thrombosis.6 In patientswith an underlying malignant disease, the incidence of
thrombosis associated with the use of central venous
catheters is estimated to be up to 30%.1,7-11 A feared
complication is progression of thrombosis into the SVC.
The symptoms caused by a vena cava thrombosis
depend on the time of thrombus progression to ﬂow-
Fig 5. Venous inﬂow after restoration of the superior vena
cava (SVC) with port-a-cath in place.
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June 2019limiting obstruction and the capacity of collateral vein
drainage through the azygos vein, internal mammary
veins, lateral thoracic vein, and paraspinal and esopha-
geal veins.2,12
If there is an acute occlusion of the SVC, the most
common symptoms are swelling of the face and neck
and arms, cyanosis, venous stasis on the shoulders and
neck, orthopnea, and dyspnea. Headaches, dizziness,
syncope, confusion, and somnolence (caused by
increasing intracranial pressure) as well as pulmonary
embolism and hemodynamic instability can quickly
lead to life-threatening situations that are associated
with unfavorable outcomes.2
In the past, SVC syndrome not associated with cancer
has been treated conservatively with anticoagulants,
diuretics, and corticosteroids, keeping the patient in an
upright position with head elevation. A surgical treat-
ment option is a median sternotomy with venous bypass
graft.13 In past years, endovascular recanalization proced-
ures have evolved as a mainstay of invasive therapy to
enable quick relief from symptoms in these vascular
emergencies.1 Catheter-based therapy and thrombolysis
must be considered in acute onset of SVC syndrome(symptoms <14 days, progressive symptoms, life-
threatening situations).2,8 Computed tomography angi-
ography is recommended to exclude the most common
causes (tumors, lymphoma, struma) of SVC syndrome, to
exclude pulmonary embolism, and to evaluate proximal
thrombosis extension. For anatomic reasons, venoplasty
with stenting is necessary when there is a relevant
chronic stenosis (usually due to ﬁbrosis or tumor mass)
left after the thrombus burden is dissolved because of
better patency rates after stenting in those cases than
with angioplasty alone. The technical success rate of
stenting of the SVC or its branches is 95% to 100%,
with a 2-year primary patency rate up to 76% and sec-
ondary patency rates up to 95%.14 Acute complications
of stent placement for SVC syndrome have been
reported in 3% to 7% of patients, including infection, pul-
monary embolism, stent migration, hematoma at the
insertion site, supraventricular arrhythmia, bleeding,
and perforation (rarely).
Because pulmonary embolism as a complication of
SVC stenting is rare and placement of an SVC ﬁlter bears
the risk of severe complications, SVC ﬁlter placement to
prevent pulmonary embolism should be performed
only in special situations.1 In situ catheters (eg, port-a-
cath, hemodialysis catheters) pose the problem that
they would be jailed by stent placement between the
stent and the vessel wall and hence would be compro-
mised in their function.15
CONCLUSIONS
To avoid catheter removal and reinsertion with the
associated risks (bleeding, pneumothorax, rethrombo-
sis, thrombosis progression, pulmonary embolism,
infection) and to minimize health care-related cost,
single-session temporary snaring of the catheter with
endovascular replacement is a feasible treatment
option after thrombectomy and therapy for the SVC
syndrome.7
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